Difluprednate
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
[(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate
|
|
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a609025 |
| Licence data | US FDA:link |
| Legal status |
|
| Routes of administration |
topical dermatologic |
| Identifiers | |
| CAS Number | 23674-86-4  |
| ATC code | D07AC19 (WHO) |
| PubChem | CID: 32037 |
| DrugBank | DB06781  |
| ChemSpider | 391990 |
| UNII | S8A06QG2QE |
| KEGG | D01266 |
| ChEMBL | CHEMBL1201749 |
| Chemical data | |
| Formula | C27H34F2O7 |
| Molecular mass | 508.551 |
| (what is this?) (verify) |
|
Difluprednate is a corticosteroid, It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.
Approval
On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain.[1] It is marketed by Alcon under the tradename Durezol.
Clinical trials
Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating difluprednate for the treatment of anterior uveitis.[2]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ ClinicalTrials.gov
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
